166 related articles for article (PubMed ID: 35609326)
1. Diabetes regulated anti-inflammatory lncRNA is overexpressed in triple-negative breast cancer and predicts chemoresistance and tumor recurrence.
Wang P; Peng W; Peng J
Bioengineered; 2022 May; 13(5):12718-12725. PubMed ID: 35609326
[TBL] [Abstract][Full Text] [Related]
2. LncRNA DRAIR is a novel prognostic and diagnostic biomarker for gastric cancer.
Jin T
Mamm Genome; 2021 Dec; 32(6):503-507. PubMed ID: 34510245
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.
Shin VY; Chen J; Cheuk IW; Siu MT; Ho CW; Wang X; Jin H; Kwong A
Cell Death Dis; 2019 Mar; 10(4):270. PubMed ID: 30894512
[TBL] [Abstract][Full Text] [Related]
4. Up-regulated lncRNA GAS5 promotes chemosensitivity and apoptosis of triple-negative breast cancer cells.
Li J; Li L; Yuan H; Huang XW; Xiang T; Dai S
Cell Cycle; 2019 Aug; 18(16):1965-1975. PubMed ID: 31282278
[TBL] [Abstract][Full Text] [Related]
5. LncRNA PTCSC3 inhibits triple-negative breast cancer cell proliferation by downregulating lncRNA H19.
Wang N; Hou M; Zhan Y; Sheng X
J Cell Biochem; 2019 Sep; 120(9):15083-15088. PubMed ID: 31026090
[TBL] [Abstract][Full Text] [Related]
6. LncRNA AWPPH and miRNA-21 regulates cancer cell proliferation and chemosensitivity in triple-negative breast cancer by interacting with each other.
Liu AN; Qu HJ; Gong WJ; Xiang JY; Yang MM; Zhang W
J Cell Biochem; 2019 Sep; 120(9):14860-14866. PubMed ID: 31033015
[TBL] [Abstract][Full Text] [Related]
7. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
[TBL] [Abstract][Full Text] [Related]
8. Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer.
Wu J; Xu W; Ma L; Sheng J; Ye M; Chen H; Zhang Y; Wang B; Liao M; Meng T; Zhou Y; Chen H
Aging (Albany NY); 2021 Jul; 13(14):18191-18222. PubMed ID: 34289449
[TBL] [Abstract][Full Text] [Related]
9. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling.
Zheng S; Li M; Miao K; Xu H
J Cell Biochem; 2020 Mar; 121(3):2225-2235. PubMed ID: 31692053
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer.
Zuo Y; Li Y; Zhou Z; Ma M; Fu K
Biomed Pharmacother; 2017 Nov; 95():922-928. PubMed ID: 28915533
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
[TBL] [Abstract][Full Text] [Related]
12. Noncoding RNAs in triple negative breast cancer: Mechanisms for chemoresistance.
Xia M; Zu X; Chen Z; Wen G; Zhong J
Cancer Lett; 2021 Dec; 523():100-110. PubMed ID: 34601022
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNAs in triple-negative breast cancer: A new frontier in the regulation of tumorigenesis.
Thakur KK; Kumar A; Banik K; Verma E; Khatoon E; Harsha C; Sethi G; Gupta SC; Kunnumakkara AB
J Cell Physiol; 2021 Dec; 236(12):7938-7965. PubMed ID: 34105151
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer.
Tang T; Cheng Y; She Q; Jiang Y; Chen Y; Yang W; Li Y
Biomed Pharmacother; 2018 Nov; 107():338-346. PubMed ID: 30098551
[TBL] [Abstract][Full Text] [Related]
15. Long Noncoding RNA Highly Up-regulated in Liver Cancer Predicts Unfavorable Outcome and Regulates Metastasis by MMPs in Triple-negative Breast Cancer.
Shi F; Xiao F; Ding P; Qin H; Huang R
Arch Med Res; 2016 Aug; 47(6):446-453. PubMed ID: 27986124
[TBL] [Abstract][Full Text] [Related]
16. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
17. LncRNA TCONS_l2_00002973 correlates with less advanced tumor stage and favorable survival, and also inhibits cancer cells proliferation while enhancing apoptosis in triple-negative breast cancer.
Yan J; Wang R; Wu Z
J BUON; 2019; 24(2):535-542. PubMed ID: 31128002
[TBL] [Abstract][Full Text] [Related]
18. LncRNA LINC00173 enhances triple-negative breast cancer progression by suppressing miR-490-3p expression.
Fan H; Yuan J; Li X; Ma Y; Wang X; Xu B; Li X
Biomed Pharmacother; 2020 May; 125():109987. PubMed ID: 32058222
[TBL] [Abstract][Full Text] [Related]
19. YTHDF1 enhances stemness and chemoresistance in triple-negative breast cancer cells by upregulating SIAH2.
Wu A; Wang X; Zhang F; Yang X; Quan Y; Dong J; Lai Y; Yang D; Sun J; Wang M
Mol Carcinog; 2024 Mar; 63(3):417-429. PubMed ID: 37983722
[TBL] [Abstract][Full Text] [Related]
20. lncRNA DRAIR is downregulated in diabetic monocytes and modulates the inflammatory phenotype via epigenetic mechanisms.
Reddy MA; Amaram V; Das S; Tanwar VS; Ganguly R; Wang M; Lanting L; Zhang L; Abdollahi M; Chen Z; Wu X; Devaraj S; Natarajan R
JCI Insight; 2021 Jun; 6(11):. PubMed ID: 33945509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
